ThromboGenics is conducting a number of clinical trials to assess the safety and efficacy of its experimental drug compounds. We conduct these trials according to the highest ethical standards as we look to provide physicians and patients with the best possible clinical data to allow informed therapeutic decisions.
Ongoing post-marketing trials
ThromboGenics currently has several post-marketing studies ongoing. These studies look to gather information on drug effects in various populations and possible side effects associated with long-term use. The studies include:
• Ocriplasmin Research to Better Inform Treatment (ORBIT): a large, multicenter, prospective observational study assessing the clinical outcomes and safety of patients receiving JETREA® in a real-world setting for the treatment of symptomatic VMA/VMT following standard of care from US retina clinics.
• Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion including Macular Hole (OASIS): a randomized, sham-controlled, double-masked study, assessing the efficacy and safety of a JETREA® in a 24-month period post-injection.
• Ocriplasmin Ellipsoid Zone Retrospective Data Collection Study (OZONE): a retrospective US patient study designed to capture more data to characterize the anatomic and symptomatic changes that potentially occur in the six months immediately after treatment with JETREA® for symptomatic VMA.
For a complete overview of ongoing and completed clinical trials, please refer to clinicaltrials.gov. This website is managed by the U.S. National Institutes of Health and gives an overview of clinical trials conducted worldwide